For Immediate Release
Contact: info@globalcancertechnology.com
GCT-007 CONTINUES TO RECEIVE EXCEPTIONAL GLIOBLASTOMA PRE-CLINICAL
RESULTS
GCT-007 INCREASES THE SENSITIVITY TO AN IMMUNE RESPONSE IN GLIOMA
CELL LINES
San Diego, CA, March 25, 2024— Global Cancer Technology (GCT) is pleased to
announce promising pre-clinical results with its proprietary PI3 Kinase inhibitor GCT-007
in treating glioblastoma (GBM). A key problem with this class of PI3K inhibitors has been
elements of systemic toxicity resulting from its use. Based on the distinct mechanism by
which GCT-007 causes an increase in important immune structures, experiments were
performed to see if lower concentrations of GCT-007 could be used to provoke an
immune response while simultaneously reducing potential toxicity. The experiments
were performed by Dr. Richard Tobin and his team from CU Anschutz Medical School,
Department of Surgery. The new data show that treatment with GCT-007 can increase
the likelihood of an immune response to glioblastoma.
“We are delighted to see the positive effects of lowering the GCT-007 concentration in this
pre-clinical study for the treatment of GBM and look forward to continuing our productive
and exciting collaboration with Dr. Tobin,” said Dr. M. Karen Newell Rogers, Chief
Scientific Consultant for GCT.
“We are impressed with the pre-clinical advancement of GCT-007 in glioblastoma,”
commented Dr. Tobin.
“Global Cancer Technology is conducting pre-clinical studies on breast cancer and glioblastoma
at the University of Colorado, and we are very pleased with the ongoing collaboration,” added
John Clark, the CEO of Global Cancer Technology.
———————————————————————————
